{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T22:26:48Z","timestamp":1790029608075,"version":"4.0.1"},"reference-count":71,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Japan Drug Development & Medical Affairs"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,31]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This real-world study evaluated the effectiveness of baricitinib on the activities of daily living and health-related quality of life in patients with rheumatoid arthritis in Japan, and it explored the association between early pain and fatigue improvements and 12-month remission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study involved patients with rheumatoid arthritis aged \u226520 who initiated baricitinib and were followed for 12\u00a0months. Patient-reported outcomes were assessed using a visual analogue scale, the Locomo 5, the EQ-5D-5L, and the SF-36 subscales.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study included 353 patients (mean age of 63.4\u00a0years). Baricitinib substantially reduced pain levels from a mean (SD) of 48.4 (26.5) mm, fatigue levels from 42.3 (28.3) mm, and morning stiffness from 51.8 (126.9) min at baseline, to 25.2 (21.4) mm, 24.3 (22.7) mm, and 15.8 (38.7) min, respectively, at 12\u00a0months. Clinically meaningful improvements were observed in activities of daily living [Locomo 5 scores: 6.9 (5.7) to 4.7 (5.3)] and health-related quality of life [EQ-5D-5L index scores: 0.700 (0.217) to 0.829 (0.166)] over 12\u00a0months. Logistic regression analysis revealed that early improvements in pain and fatigue were predictive of disease remission at 12\u00a0months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Baricitinib improved patient-reported outcomes in patients with rheumatoid arthritis in Japan, with early symptom relief predicting mid-term disease remission. To complement this abstract, a video abstract is available online.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/mr\/roag032","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:40:00Z","timestamp":1773924000000},"page":"724-736","source":"Crossref","is-referenced-by-count":1,"title":["Patient-reported outcomes in patients with rheumatoid arthritis treated with baricitinib: A prospective observational study in Japan"],"prefix":"10.1093","volume":"36","author":[{"given":"Yuko","family":"Kaneko","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , 35 Shinanomachi, Shinjuku-ku, Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Tsujimoto","sequence":"additional","affiliation":[{"name":"Japan Drug Development & Medical Affairs, Eli Lilly Japan K.K. , Kobe ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izumi","family":"Sato","sequence":"additional","affiliation":[{"name":"Japan Drug Development & Medical Affairs, Eli Lilly Japan K.K. , Kobe ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisuke","family":"Kojima","sequence":"additional","affiliation":[{"name":"Japan Drug Development & Medical Affairs, Eli Lilly Japan K.K. , Kobe ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Rheumatology\/Rheumatic Disease Center, Dokkyo Medical University , 880 Kitakobayashi, Mibu, Shimotsugagun, Tochigi ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"2026083106414699700_ref1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/14397595.2013.854059","article-title":"Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I)","volume":"24","author":"Yamanaka","year":"2014","journal-title":"Mod Rheumatol"},{"key":"2026083106414699700_ref2","doi-asserted-by":"crossref","DOI":"10.33590\/emjrheumatol\/COPA4036","article-title":"Ageing population and landscape of rheumatoid arthritis treatment in Japan","author":"Kubo","year":"2024","journal-title":"EMJ Rheumatol"},{"key":"2026083106414699700_ref3","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1136\/annrheumdis-2019-215920","article-title":"Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the global burden of disease study 2017","volume":"78","author":"Safiri","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2026083106414699700_ref4","first-page":"100240","article-title":"Clinical remission of rheumatoid arthritis in a multicenter real-world study in Asia-Pacific region","volume":"15","author":"Sun","year":"2021","journal-title":"Lancet Reg Health West Pac"},{"key":"2026083106414699700_ref5","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1080\/14397595.2017.1416940","article-title":"Residual symptoms and disease burden among patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review","volume":"28","author":"Ishida","year":"2018","journal-title":"Mod Rheumatol"},{"key":"2026083106414699700_ref6","doi-asserted-by":"crossref","first-page":"e594","DOI":"10.1016\/S2665-9913(23)00211-4","article-title":"Global, regional, and national burden of rheumatoid arthritis, 1990-2020, and projections to 2050: a systematic analysis of the global burden of disease study 2021","volume":"5","author":"Collaborators GBDRA","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"2026083106414699700_ref7","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3899\/jrheum.161404","article-title":"Importance of obtaining remission for work productivity and activity of patients with rheumatoid arthritis","volume":"44","author":"Kim","year":"2017","journal-title":"J Rheumatol"},{"key":"2026083106414699700_ref8","doi-asserted-by":"crossref","first-page":"742","DOI":"10.3109\/s10165-012-0729-3","article-title":"Analysis of direct medical and nonmedical costs for care of rheumatoid arthritis patients using the large cohort database, IORRA","volume":"23","author":"Tanaka","year":"2013","journal-title":"Mod Rheumatol"},{"key":"2026083106414699700_ref9","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.3899\/jrheum.151177","article-title":"The reporting of patient-reported outcomes in studies of patients with rheumatoid arthritis: a systematic review of 250 articles","volume":"43","author":"Kilic","year":"2016","journal-title":"J Rheumatol"},{"key":"2026083106414699700_ref10","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2026083106414699700_ref11","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/rheumatology\/keae012","article-title":"Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis up to 6.5 years of treatment: results of a long-term study","volume":"63","author":"Caporali","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2026083106414699700_ref12","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3899\/jrheum.150613","article-title":"Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis receiving background methotrexate therapy: a 12-week, double-blind, randomized placebo-controlled study","volume":"43","author":"Tanaka","year":"2016","journal-title":"J Rheumatol"},{"key":"2026083106414699700_ref13","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.39953","article-title":"Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and No or limited prior disease-modifying antirheumatic drug treatment","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2026083106414699700_ref14","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"2026083106414699700_ref15","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1001\/jama.2023.4855","article-title":"Randomized trials vs real-world evidence: how can both inform decision-making?","volume":"329","author":"Sheldrick","year":"2023","journal-title":"JAMA."},{"key":"2026083106414699700_ref16","doi-asserted-by":"crossref","first-page":"107074","DOI":"10.1016\/j.phrs.2024.107074","article-title":"Comparing clinical trial population representativeness to real-world users of 17 biologics approved for immune-mediated inflammatory diseases: an external validity analysis of 66,639 biologic users from the Italian VALORE project","volume":"200","author":"Ingrasciotta","year":"2024","journal-title":"Pharmacol Res"},{"key":"2026083106414699700_ref17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/mr\/roae064","article-title":"Safety of baricitinib in Japanese patients with rheumatoid arthritis in clinical use: 3-year data of all-case postmarketing surveillance study","volume":"35","author":"Okamoto","year":"2025","journal-title":"Mod Rheumatol"},{"key":"2026083106414699700_ref18","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/mr\/roac089","article-title":"Safety and effectiveness of baricitinib for rheumatoid arthritis in Japanese clinical practice: 24-week results of all-case post-marketing surveillance","volume":"33","author":"Takagi","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2026083106414699700_ref19","article-title":"Retention of baricitinib-treated patients with rheumatoid arthritis in Japan: Interim results from a prospective observational cohort study","author":"Kaneko","year":"2025","journal-title":"Mod Rheumatol"},{"key":"2026083106414699700_ref20","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2026083106414699700_ref21","first-page":"S100","article-title":"The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis","volume":"23","author":"Aletaha","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2026083106414699700_ref22","doi-asserted-by":"crossref","first-page":"R796","DOI":"10.1186\/ar1740","article-title":"Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score","volume":"7","author":"Aletaha","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"2026083106414699700_ref23","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/ard.2007.084459","article-title":"Validation of the 28-joint disease activity score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate","volume":"68","author":"Wells","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2026083106414699700_ref24","volume-title":"EQ-5D-5L User guide. Version 3.0. September 19","author":"The EuroQoL Group"},{"key":"2026083106414699700_ref25","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jos.2021.05.001","article-title":"Development of a simple screening tool based on the 5-question geriatric locomotive function scale for locomotive syndrome","volume":"27","author":"Kobayashi","year":"2022","journal-title":"J Orthop Sci"},{"key":"2026083106414699700_ref26","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1136\/bmj.306.6890.1437","article-title":"Short form 36 (SF36) health survey questionnaire: normative data for adults of working age","volume":"306","author":"Jenkinson","year":"1993","journal-title":"BMJ"},{"key":"2026083106414699700_ref27","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14051718","article-title":"Impact and prevalence of depression and anxiety in rheumatoid arthritis-a cross-sectional study with self-reported questionnaires","volume":"14","author":"Ionescu","year":"2025","journal-title":"J Clin Med"},{"key":"2026083106414699700_ref28","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/mr\/roac105","article-title":"Association between patient-reported outcomes and impairments in work and activity in patients with rheumatoid arthritis in clinical remission: a retrospective analysis using the IORRA database","volume":"33","author":"Sakai","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2026083106414699700_ref29","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3109\/17453678909149276","article-title":"Locomotion score in rheumatoid arthritis","volume":"60","author":"Larsson","year":"1989","journal-title":"Acta Orthop Scand"},{"key":"2026083106414699700_ref30","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1002\/acr.20621","article-title":"Measures of rheumatoid arthritis disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score with 28-Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Activity Score (PAS) and Patient Activity Score-II (PASII), Routine Assessment of Patient Index Data (RAPID), Rheumatoid Arthritis Disease Activity Index (RADAI) and Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5), Chronic Arthritis Systemic Index (CASI), Patient-Based Disease Activity Score with ESR (PDAS1) and Patient-Based Disease Activity Score without ESR (PDAS2), and Mean Overall Index for Rheumatoid Arthritis (MOI-RA)","volume":"63","author":"Anderson","year":"2011","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"2026083106414699700_ref31","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","article-title":"Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations","volume":"9","author":"Dworkin","year":"2008","journal-title":"J Pain"},{"key":"2026083106414699700_ref32","doi-asserted-by":"crossref","first-page":"rkaf006","DOI":"10.1093\/rap\/rkaf006","article-title":"Effectiveness of baricitinib versus sarilumab on disease activity in patients with RA: a propensity score matching study","volume":"9","author":"Yukishima","year":"2025","journal-title":"Rheumatol Adv Pract"},{"key":"2026083106414699700_ref33","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s41927-024-00446-y","article-title":"Efficacy and safety of baricitinib in rheumatoid arthritis patients with moderate renal impairment: a multicenter propensity score matching study","volume":"8","author":"Maeyama","year":"2024","journal-title":"BMC Rheumatol"},{"key":"2026083106414699700_ref34","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in patients with refractory rheumatoid arthritis","volume":"374","author":"Genovese","year":"2016","journal-title":"N Engl J Med"},{"key":"2026083106414699700_ref35","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","article-title":"Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study","volume":"76","author":"Dougados","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026083106414699700_ref36","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1136\/annrheumdis-2017-211259","article-title":"Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study","volume":"76","author":"Keystone","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026083106414699700_ref37","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1002\/acr.21747","article-title":"Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: results from a prospective multinational study","volume":"64","author":"Tubach","year":"2012","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"2026083106414699700_ref38","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s40744-023-00594-6","article-title":"A real-world effectiveness study using a mobile application to evaluate early outcomes with upadacitinib in rheumatoid arthritis","volume":"10","author":"Harrold","year":"2023","journal-title":"Rheumatol Ther."},{"key":"2026083106414699700_ref39","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3899\/jrheum.2023-0752","article-title":"Treatment patterns and effectiveness of tofacitinib in patients initiating therapy for rheumatoid arthritis: results from the CorEvitas rheumatoid arthritis registry","volume":"51","author":"Pappas","year":"2024","journal-title":"J Rheumatol"},{"key":"2026083106414699700_ref40","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/mr\/roac152","article-title":"Illustrations of rheumatoid arthritis symptoms to promote communication between patients and physicians","volume":"34","author":"Kaneko","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2026083106414699700_ref41","volume-title":"The 69th Annual Scientific Meeting of the Japan College of Rheumatology April 24\u201326, 2025","author":"Kaneko"},{"key":"2026083106414699700_ref42","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3899\/jrheum.140389","article-title":"Assessment of fatigue in rheumatoid arthritis: a psychometric comparison of single-item, multiitem, and multidimensional measures","volume":"42","author":"Oude Voshaar","year":"2015","journal-title":"J Rheumatol"},{"key":"2026083106414699700_ref43","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/rheumatology\/ker162","article-title":"Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis","volume":"51","author":"Chauffier","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"2026083106414699700_ref44","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/nrrheum.2016.112","article-title":"Affective disturbance in rheumatoid arthritis: psychological and disease-related pathways","volume":"12","author":"Sturgeon","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"2026083106414699700_ref45","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1007\/s00296-018-4102-5","article-title":"Fatigue in early, intensively treated and tight-controlled rheumatoid arthritis patients is frequent and persistent: a prospective study","volume":"38","author":"Walter","year":"2018","journal-title":"Rheumatol Int"},{"key":"2026083106414699700_ref46","article-title":"Treatment effect of baricitinib on fatigue: mediation analysis results from two phase 3 trials [abstract]","volume":"73","author":"Fautrel","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026083106414699700_ref47","article-title":"Biologic interventions for fatigue in rheumatoid arthritis","volume":"2016","author":"Almeida","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2026083106414699700_ref48","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s40265-024-02059-8","article-title":"Biologics or Janus kinase inhibitors in rheumatoid arthritis patients who are insufficient responders to conventional anti-rheumatic drugs","volume":"84","author":"Favalli","year":"2024","journal-title":"Drugs."},{"key":"2026083106414699700_ref49","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031246","article-title":"Janus kinase inhibitors improve disease activity and patient-reported outcomes in rheumatoid arthritis: a systematic review and meta-analysis of 24,135 patients","volume":"23","author":"Toth","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026083106414699700_ref50","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/ggi.14162","article-title":"Relationship between locomotive syndrome, frailty and sarcopenia: locomotive syndrome overlapped in the majority of frailty and sarcopenia patients","volume":"21","author":"Ide","year":"2021","journal-title":"Geriatr Gerontol Int"},{"key":"2026083106414699700_ref51","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/acr.25282","article-title":"Frailty and risk of serious infections in patients with rheumatoid arthritis treated with biologic or targeted-synthetic disease-modifying antirheumatic drugs","volume":"76","author":"Singh","year":"2024","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026083106414699700_ref52","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1093\/rheumatology\/keaa084","article-title":"Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb\/III study","volume":"59","author":"Kameda","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2026083106414699700_ref53","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s40744-024-00694-x","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis refractory to biologic DMARDs: results through week 216 from the SELECT-CHOICE study","volume":"11","author":"Rubbert-Roth","year":"2024","journal-title":"Rheumatol Ther"},{"key":"2026083106414699700_ref54","doi-asserted-by":"crossref","first-page":"e004476","DOI":"10.1136\/rmdopen-2024-004476","article-title":"Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study","volume":"10","author":"Buch","year":"2024","journal-title":"RMD Open."},{"key":"2026083106414699700_ref55","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial","volume":"322","author":"Genovese","year":"2019","journal-title":"JAMA."},{"key":"2026083106414699700_ref56","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.3899\/jrheum.110392","article-title":"It's good to feel better but it's better to feel good and even better to feel good as soon as possible for as long as possible. Response criteria and the importance of change at OMERACT 10","volume":"38","author":"Strand","year":"2011","journal-title":"J Rheumatol"},{"key":"2026083106414699700_ref57","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/1756-185X.14066","article-title":"Health-related quality of life in rheumatoid arthritis: systematic review and meta-analysis of EuroQoL (EQ-5D) utility scores from Asia","volume":"24","author":"Haridoss","year":"2021","journal-title":"Int J Rheum Dis"},{"key":"2026083106414699700_ref58","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s11136-015-1108-2","article-title":"Japanese population norms for preference-based measures: EQ-5D-3L, EQ-5D-5L, and SF-6D","volume":"25","author":"Shiroiwa","year":"2016","journal-title":"Qual Life Res"},{"key":"2026083106414699700_ref59","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.jval.2021.03.010","article-title":"Japanese population norms of EQ-5D-5L and health utilities index mark 3: disutility catalog by disease and symptom in community settings","volume":"24","author":"Shiroiwa","year":"2021","journal-title":"Value Health"},{"key":"2026083106414699700_ref60","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1477-7525-11-59","article-title":"Minimal clinically important differences for the EQ-5D and QWB-SA in post-traumatic stress disorder (PTSD): results from a doubly randomized preference trial (DRPT)","volume":"11","author":"Le","year":"2013","journal-title":"Health Qual Life Outcomes"},{"key":"2026083106414699700_ref61","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1080\/14397595.2019.1709681","article-title":"Response to tocilizumab and work productivity in patients with rheumatoid arthritis: 2-year follow-up of FIRST ACT-SC study","volume":"31","author":"Tanaka","year":"2021","journal-title":"Mod Rheumatol"},{"key":"2026083106414699700_ref62","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/1529-0131(200007)43:7<1478::AID-ANR10>3.0.CO;2-M","article-title":"Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis","volume":"43","author":"Kosinski","year":"2000","journal-title":"Arthritis Rheum"},{"key":"2026083106414699700_ref63","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1002\/art.42617","article-title":"Baricitinib improves bone properties and biomechanics in patients with rheumatoid arthritis: results of the prospective interventional BARE BONE trial","volume":"75","author":"Simon","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2026083106414699700_ref64","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s13075-019-2059-8","article-title":"Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs","volume":"21","author":"Strand","year":"2019","journal-title":"Arthritis Res Ther."},{"key":"2026083106414699700_ref65","doi-asserted-by":"crossref","first-page":"e000496","DOI":"10.1136\/rmdopen-2017-000496","article-title":"Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials","volume":"3","author":"Strand","year":"2017","journal-title":"RMD Open"},{"key":"2026083106414699700_ref66","doi-asserted-by":"crossref","first-page":"e000602","DOI":"10.1136\/rmdopen-2017-000602","article-title":"Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis","volume":"4","author":"Strand","year":"2018","journal-title":"RMD Open"},{"key":"2026083106414699700_ref67","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"2026083106414699700_ref68","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s13075-019-2030-8","article-title":"Radiographic progression can still occur in individual patients with low or moderate disease activity in the current treat-to-target paradigm: real-world data from the Dutch rheumatoid arthritis monitoring (DREAM) registry","volume":"21","author":"Ten Klooster","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2026083106414699700_ref69","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1136\/annrheumdis-2024-eular.1469","article-title":"POS0643 association of early remission on clinical and patient-reported outcomes in patients with rheumatoid arthritis: post-hoc analysis of data from the select-compare study","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2026083106414699700_ref70","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/acr.22787","article-title":"Predictors of fatigue in rheumatoid arthritis patients in remission or in a low disease activity state","volume":"68","author":"Olsen","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026083106414699700_ref71","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40744-025-00747-9","article-title":"Effective second-line b\/tsDMARDs for patients with rheumatoid arthritis unresponsive to FIRST-line b\/tsDMARDs from the FIRST registry","volume":"12","author":"Kanda","year":"2025","journal-title":"Rheumatol Ther"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roag032\/67461444\/roag032.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/5\/724\/67461444\/roag032.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/5\/724\/67461444\/roag032.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T10:42:05Z","timestamp":1788172925000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/36\/5\/724\/8534421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":71,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,4,9]]},"published-print":{"date-parts":[[2026,8,31]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roag032","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,4,9]]}}}